Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Free Report) VP Mary E. Godwin sold 35,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $2.85, for a total value of $99,750.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Nautilus Biotechnology Price Performance
Shares of NASDAQ NAUT traded down $0.03 during mid-day trading on Wednesday, reaching $2.87. 94,625 shares of the company’s stock were exchanged, compared to its average volume of 74,260. The firm has a market capitalization of $359.51 million, a price-to-earnings ratio of -5.22 and a beta of 1.20. Nautilus Biotechnology, Inc. has a 52 week low of $2.19 and a 52 week high of $3.62. The firm has a 50-day moving average price of $2.57 and a two-hundred day moving average price of $2.59.
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same period in the prior year, the firm earned ($0.13) earnings per share. As a group, sell-side analysts forecast that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current fiscal year.
Institutional Investors Weigh In On Nautilus Biotechnology
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Guggenheim assumed coverage on Nautilus Biotechnology in a research note on Thursday, June 27th. They set a “buy” rating and a $6.00 price objective on the stock. Jefferies Financial Group started coverage on Nautilus Biotechnology in a research note on Monday, June 3rd. They set a “hold” rating and a $3.00 price objective on the stock.
View Our Latest Stock Analysis on NAUT
Nautilus Biotechnology Company Profile
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Featured Stories
- Five stocks we like better than Nautilus Biotechnology
- What to Know About Investing in Penny Stocks
- How Much Can You Make in Stocks in One Month?
- Best Stocks Under $5.00
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Invest in Insurance Companies: A Guide
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.